ECG Electrodes and Skin Interface Patents: Who Leads and Where Filings Are Headed
Concentrated at the top. the five leading assignees hold 27.2% of all 1,858 records in scope, and the top ten hold 36.5% — well short of a monopoly on the space. Filings rose from 67 in 2017 to a peak of 140 in 2019, then eased to 126 by 2021 and 54 by 2024 — a 57% decline over that three-year window. 2025 and 2026 figures will rise as publication catches up; they should not yet be read as continued decline.
- 1BARDY DIAGNOSTICS INC8.6%
- 2KONINKLIJKE PHILIPS NV7.2%
- 3ZOLL MEDICAL CORPORATION5.5%
- 4ELEMENT SCIENCE INC3.4%
- 5AKOUOS INC2.6%
See the full ecg electrodes and skin interface analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about ECG electrode patents
Who holds the most ECG electrode and skin-interface patents?
The leading assignee in this corpus holds 159 records, well ahead of the fifth-place figure of 48 and tenth-place figure of 28. Even so, the top five assignees combined hold only 27.2% of the 1,858 records in scope, and the top ten hold 36.5%, so the field is led rather than dominated by any single company. The remaining majority of filings sit with a long tail of smaller and single-filing entrants across the full 100-company ranking.
Is patent filing in ECG electrode technology growing or slowing down?
Filings peaked at 140 records in 2019, rose again to 126 in 2021, then fell to 54 by 2024 — a 57% decline over that three-year window. That decline is real for the years it covers, but 2025 and 2026 counts are still incomplete because publication typically lags filing by around 18 months. Treat the most recent one to two years on any trend chart as understated rather than as evidence of continued decline.
What technology areas do ECG electrode patents cover most heavily?
Diagnosis and surgery classifications (IPC A61B) appear on 71.3% of the 1,858 records, and electrotherapy classifications (A61N) appear on 34.0%, reflecting that most filings address sensing, monitoring or therapy delivery through the electrode. Supporting areas like healthcare informatics, medicinal preparations, adhesives and sterilising methods each cover under 6% of records, meaning claim density there is much lower than in the core sensing and therapy classes.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on ECG Electrodes and Skin Interface covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.